Coya Therapeutics, Inc. (COYA) - Q3 2025 Filing Summary
Business Context and Reporting Period
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies to enhance Regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer and an emerging growth company. As of November 10, 2025, there were 20,924,456 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $3.56 million | $0 | $3.99 million | $3.55 million |
| Total Operating Expenses | $6.00 million | $4.45 million | $20.51 million | $16.72 million |
| Net Loss | $(2.12) million | $(4.02) million | $(15.52) million | $(11.97) million |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.26) | $(0.93) | $(0.80) |
| Cash and Cash Equivalents (Sept 30, 2025) | $28.13 million | |||
| Accumulated Deficit (Sept 30, 2025) | $(56.25) million | |||
| Net Cash Used in Operating Activities (YTD) | $(9.73) million | $(7.88) million |
Material Changes vs. Prior Period
- Revenue Recognition: Collaboration revenue increased significantly in Q3 2025 ($3.56M) compared to zero in Q3 2024. This was driven by the immediate recognition of $3.3 million in license revenue following the FDA's acceptance of the Investigational New Drug (IND) application for COYA 302 for ALS treatment.
- Expense Growth: Total operating expenses rose by $1.55 million in Q3 2025 compared to Q3 2024. Research and Development (R&D) expenses increased by $0.69 million, largely due to the reclassification of COYA 302 expenses from preclinical to clinical status and increased internal R&D costs.
- In-Process R&D: The company recorded $0.52 million in in-process R&D expenses in Q3 2025 (compared to $0 in Q3 2024) related to milestone payments to license partners (Dr. Reddy's and ARScience) triggered by the IND acceptance.
- Liquidity: Cash balances decreased from $38.34 million at year-end 2024 to $28.13 million at September 30, 2025, reflecting a net cash burn of $10.21 million for the nine-month period.
Guidance, Outlook, and Risks
- Capital Raise: On October 23, 2025, the company entered into an underwriting agreement for a public offering of 4,181,818 shares at $5.50 per share. The offering closed on October 27, 2025, generating approximately $23.0 million in gross proceeds.
- Liquidity Outlook: Management expects that existing cash ($28.1 million) combined with the new offering proceeds ($23.0 million) will fund operations for at least one year following the issuance of these financial statements. Substantial additional financing will be required thereafter.
- Development Milestones: The company is advancing COYA 302 into a Phase 2 clinical trial for ALS. Future revenue is contingent on achieving regulatory and commercial milestones under the Dr. Reddy's Development Agreement, which includes potential payments of up to $40 million in development milestones and $677.3 million in sales milestones.
- Risk Factors: The filing highlights risks associated with the ongoing U.S. government shutdown (as of September 30, 2025), which could delay FDA review processes. Additionally, the company has incurred losses since inception and has no products approved for commercial sale.
Key Investor Verification Points
- Runway Validation: Verify the net proceeds from the October 2025 offering after deducting underwriting discounts and expenses to confirm the actual cash runway.
- Revenue Sustainability: Assess the timing of the next $4.2 million milestone payment from Dr. Reddy's, which is contingent on the dosing of the first patient in the Phase 2 trial.
- Burn Rate Trends: Monitor the quarterly cash burn rate, which accelerated to $9.73 million for the nine months ended September 2025, to evaluate the necessity of future capital raises.
- Regulatory Timeline: Track the impact of the government shutdown on the FDA's ability to review the IND and subsequent clinical trial approvals.